CVKD - Cadrenal Therapeutics, Inc. Common Stock

CVKD - Cadrenal Therapeutics, Inc. Common Stock

https://www.cadrenal.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

PR Newswire • 1 year, 3 months ago • score: 0.09

PONTE VEDRA, Fla., May 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ( Nasdaq: CVKD ) , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant ( blood thinner ) designed to prevent heart attacks, strokes and deaths due to blood clots in ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$22.90

52W Low

$6.89

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.98

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.21

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

6.31

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

27.84%

Institutions (25–75% balanced)

7.23%

Shares Outstanding

2,046,800

Float

1,476,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-8.88

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-3.40%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.3910

Previous

0.4185

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025